SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Moderna, Inc. - MRNA
StockNews.AI • 589 days
Low Materiality0/10
Information
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...
Original sourceAI Summary
Pomerantz LLP investigates claims regarding Moderna's securities fraud or unlawful practices. Moderna's mRNA-1345 vaccine for RSV in older adults had efficacy of 78.7%. Moderna's vaccine after 18 months was only 49.9%-50.3% effective against RSV.
Market-Moving
- Pomerantz LLP investigates claims regarding Moderna's securities fraud or unlawful practices.
- Moderna's mRNA-1345 vaccine for RSV in older adults had efficacy of 78.7%.
- Moderna's vaccine after 18 months was only 49.9%-50.3% effective against RSV.
Key Facts
- Pomerantz LLP investigates claims regarding Moderna's securities fraud or unlawful practices.
- Moderna's mRNA-1345 vaccine for RSV in older adults had efficacy of 78.7%.
- Moderna's vaccine after 18 months was only 49.9%-50.3% effective against RSV.